21.15

1.12% -0.24

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $21.15, with a volume of 933.65K. It is down -1.12% in the last 24 hours and down -0.42% over the past month. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Previous Close:

$21.39

Open:

$21.52

24h Volume:

933.65K

Relative Volume:

1.02

Market Cap:

$2.55B

Revenue:

$434.48M

Net Income/Loss:

$68.15M

P/E Ratio:

20.94

EPS:

1.01

Net Cash Flow:

$114.96M

1W Performance:

-7.24%

1M Performance:

-0.42%

6M Performance:

+25.00%

1Y Performance:

+54.27%

1-Day Range:

$21.05

$21.63

1-Week Range:

$20.44

$22.78

52-Week Range:

$13.00

$24.27

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

167

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX	21.15	2.55B	434.48M	68.15M	114.96M	1.01
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Nov 20, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 20, 2024

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 20, 2024

Nov 19, 2024

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 19, 2024

Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan

Nov 19, 2024

GSA Capital Partners LLP Makes New $625,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat

Nov 18, 2024

Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 18, 2024

Stephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight Recommendation - MSN

Nov 18, 2024

Nov 15, 2024

Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com

Nov 15, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance

Nov 15, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat

Nov 15, 2024

Nov 14, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 14, 2024

Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga

Nov 14, 2024

Nov 13, 2024

Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com

Nov 13, 2024

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times

Nov 13, 2024

Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan

Nov 13, 2024

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St

Nov 13, 2024

Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance

Nov 13, 2024

Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 13, 2024

Nov 12, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Nov 12, 2024

Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat

Nov 12, 2024

CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Nov 11, 2024

Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat

Nov 11, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat

Nov 11, 2024

Nov 10, 2024